论文部分内容阅读
目的 探讨晚期肝癌患者肝移植术后辅助化疗的可行性、安全性和疗效。方法 分析10例原发性肝癌患者肝移植术后辅助化疗的临床资料。化疗采用FAP方案 :四氢叶酸钙 (CF) 2 0 0mg/m2 ,5 氟尿嘧啶 (5 Fu) 5 0 0mg/m2 ,静脉滴注 ,第 1～ 5天 ;阿霉素 (ADM) 4 0mg/m2 ,顺铂 (CDDP) 30mg/m2 ,静脉滴注第 1天。对化疗时机、化疗方案、免疫抑制剂和化疗的协同作用以及化疗药物的副作用进行初步评价。结果 10例患者至今存活 7例 ,最长 32个月 ,最短 9个月 ;死亡 3例 ,生存期均超过了 1年 ,其中 2例死于术后 13个月 ,1例死于 2 0个月 ,死亡原因均为肿瘤转移。化疗毒副反应轻。结论 肝癌患者肝移植术后辅助化疗是可行的、副作用小 ,有可能延长患者生存期 ;选择化疗时间对肿瘤复发和患者生存率可能有影响。
Objective To investigate the feasibility, safety and efficacy of adjuvant chemotherapy after liver transplantation in patients with advanced liver cancer. Methods Clinical data of adjuvant chemotherapy after liver transplantation in 10 patients with primary liver cancer were analyzed. Chemotherapy with FAP program: calcium folinate (CF) 200mg / m2, 5-fluorouracil 500mg / m2, intravenous drip, 1 to 5 days; doxorubicin (ADM) 40mg / m2 , Cisplatin (CDDP) 30mg / m2, the first day of intravenous infusion. The timing of chemotherapy, chemotherapy, synergistic effects of immunosuppressive agents and chemotherapy, as well as the side effects of chemotherapy drugs were initially evaluated. Results 10 patients survived so far in 7 cases, up to 32 months, the shortest 9 months; 3 died, the survival of more than 1 year, of which 2 died after 13 months and 1 died of 20 Month, the cause of death is tumor metastasis. Chemotherapy toxic side effects. Conclusions Adjuvant chemotherapy after liver transplantation is feasible in liver cancer patients with small side effects, which may prolong the survival of patients. Choosing the chemotherapy time may have an impact on tumor recurrence and patient survival.